Maxim Group Sticks to Its Buy Rating for Actinium Pharmaceuticals (ATNM)

By Carrie Williams

In a report released yesterday, Naureen Quibria from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report), with a price target of $25.00. The company’s shares closed last Tuesday at $8.34.

According to TipRanks.com, Quibria is a 3-star analyst with an average return of 8.8% and a 50.0% success rate. Quibria covers the Healthcare sector, focusing on stocks such as Fennec Pharmaceuticals, Cardiff Oncology, and Chimerix.

Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $36.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.18 and a one-year low of $5.70. Currently, Actinium Pharmaceuticals has an average volume of 228.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.